Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study

Archives of Neurology

Volumn 66, Issue 11, 2009, Pages 1345-1352

  Moraal, Bastiaan ^a   Pohl, Christoph ^b,c   Uitdehaag, Bernard M J ^a   Polman, Chris H ^a   Edan, Gilles ^e   Freedman, Mark S ^f   Hartung, Hans Peter ^d   Kappos, Ludwig ^g   Miller, David H ^h   Montalban, Xavier ⁱ   Lanius, Vivian ^b   Sandbrink, Rupert ^b,d   Barkhof, Frederik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF OTTAWA   (Canada)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DOUBLE BLIND PROCEDURE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; BRAIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; YOUNG ADULT;

EID: 70449671051     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.243     Document Type: Article

References (32)

1. Miller D, Barkhof F, Montalban X, Thompson A, Filippi M. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005;4(5):281-288. (Pubitemid 40545039)
2. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;13(3):227-231. (Pubitemid 13158528)
3. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med. 2002;346(3):158-164. (Pubitemid 34438881)
4. Beck RW, Trobe JD, Moke PS, et al; Optic Neuritis Study Group. High- and lowrisk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 2003; 121(7):944-949.
5. Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL, Castelijns JA. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol. 2004;61(2):217-221. (Pubitemid 38197554)
6. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain. 2008;131 (pt 3):808-817.
7. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain. 1997; 120(pt 11):2059-2069.
8. Tintoré M, Rovira A, Martínez MJ, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol. 2000;21(4):702-706.
9. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
10. CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology. 2002;59(7):998-1005.
11. Korteweg T, Tintoré M, Uitdehaag B, et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol. 2006;5(3):221-227.
12. Tintoré M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology. 2006;67(6):968-972. (Pubitemid 44454586)
13. Barkhof F, Rocca M, Francis G, et al; Early Treatment of Multiple Sclerosis Study Group. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a. Ann Neurol. 2003;53(6):718-724.
14. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242-1249. (Pubitemid 44563835)
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 1983;33(11):1444-1452.
16. Barkhof F, Filippi M, van Waesberghe JH, et al. Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology. 1997;49(6):1682-1688. (Pubitemid 28015137)
17. van Walderveen MA, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short- TR/short-TE (T1-weighted) spin-echo images. Neurology. 1995;45(9):1684-1690.
18. Barkhof F, Filippi M, van Waesberghe JH, Campi A, Miller DH, Adèr HJ. Interobserver agreement for diagnostic MRI criteria in suspected multiple sclerosis. Neuroradiology. 1999;41(5):347-350. (Pubitemid 29237714)
19. Uitdehaag BM, Kappos L, Bauer L, et al. Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis: a proposal for standardization. Mult Scler. 2005;11(2):227-231. (Pubitemid 40403264)
20. Molyneux PD, Tubridy N, Parker GJ, et al. The effect of section thickness on MR lesion detection and quantification in multiple sclerosis. AJNR Am J Neuroradiol. 1998;19(9):1715-1720. (Pubitemid 30413763)
21. Dolezal O, Dwyer MG, Horakova D, et al. Detection of cortical lesions is dependent on choice of slice thickness in patients with multiple sclerosis. Int Rev Neurobiol. 2007;79:475-489.
22. Barkhof F, Polman CH, Radue EW, et al. Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. Arch Neurol. 2007;64(9):1292-1298.
23. Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol. 2007;6(8):677-686.
24. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria." Ann Neurol. 2005;58(6):840-846.
25. Bink A, Schmitt M, Gaa J, Mugler JP III, Lanfermann H, Zanella FE. Detection of lesions in multiple sclerosis by 2D FLAIR and single-slab 3D FLAIR sequences at 3.0 T: initial results. Eur Radiol. 2006;16(5):1104-1110.
26. Moraal B, Roosendaal SD, Pouwels PJ, et al. Multi-contrast, isotropic, singleslab 3D MR imaging in multiple sclerosis. Eur Radiol. 2008;18(10):2311- 2320.
27. Wattjes MP, Lutterbey GG, Harzheim M, et al. Higher sensitivity in the detection of inflammatory brain lesions in patients with clinically isolated syndromes suggestive of multiple sclerosis using high field MRI: an intraindividual comparison of 1.5 T with 3.0 T. Eur Radiol. 2006;16(9):2067- 2073. (Pubitemid 44193191)
28. Bedell BJ, Narayana PA. Implementation and evaluation of a new pulse sequence for rapid acquisition of double inversion recovery images for simultaneous suppression of white matter and CSF. J Magn Reson Imaging. 1998; 8(3):544-547.
29. Geurts JJ, Pouwels PJ, Uitdehaag BM, Polman CH, Barkhof F, Castelijns JA. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion- recovery MR imaging. Radiology. 2005;236(1):254-260. (Pubitemid 40853320)
30. Nelson F, Poonawalla AH, Hou P, Huang F, Wolinsky JS, Narayana PA. Improved identification of intracortical lesions in multiple sclerosis with phasesensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol. 2007;28(9):1645-1649. (Pubitemid 47598132)
31. 2 lesions in MS: an interobserver study. J Neurol. 2002;249(6): 767-773.
32. Moraal B, Meier DS, Poppe PA, et al. Subtraction MR images in a multiple sclerosis multicenter clinical trial setting. Radiology. 2009;250(2):506-514.